Weight-Loss drug semaglutide tested as cannabis craving cure

NCT ID NCT07523633

Recruiting now Disease control Sponsor: Anders Fink-Jensen, MD, DMSci Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether semaglutide (Wegovy), a drug used for weight loss, can help adults with cannabis use disorder use less cannabis. 100 participants will receive either semaglutide or a placebo injection weekly for 20 weeks. The main goal is to see if the drug reduces total cannabis use compared to placebo, with brain scans in some participants to explore how it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (Wegovy)
What this could lead to: If it works, this could offer a new medication to help people cut down or stop cannabis use, addressing a condition with few approved treatments.
What could go wrong: This is an early Phase 2 trial with only 100 people, so results may not apply broadly. Semaglutide can cause nausea, vomiting, and other side effects, and the placebo group may also improve.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANNABIS ABUSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cannabis dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANNABIS ABUSE CANNABIS ADDICTION CANNABIS DEPENDENCE CANNABIS USE DISORDER CANNABIS USE DISORDERS

Contacts and locations

Locations

Psychiatric Center Copenhagen, Frederiksberg Hospital
RECRUITING

Frederiksberg, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.